Immuron Limited (IMRN): Net earnings per share for the last 12 months

Immuron Inc (IMRN) - corporate logo

Immuron Limited relies on an efficient outsourcing scheme for international logistics to minimize operational risks. The company's annual revenue per unit reflects the earnings per share trend, while -0.34 indicates the current level. Growth is driven by Travelan sales and the over-the-counter segment, with a scientific foundation based on innovative colostrum-derived antibodies to combat gastrointestinal infections.

IMRN (Immuron Limited) Net earnings per share for the last four quarters history from 07/04/2022 to 11/10/2026

IMRN (Immuron Ltd): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Price Immuron Inc|IMRN - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Immuron Limited|IMRN - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share Immuron|IMRN - Book Valuation of Business|Market Value to Book Value Ratio immuron.com.au|IMRN - Cumulative Company Assets
- business debt structure and liquidity details:
Debt to Equity Immuron Limited|IMRN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Immuron Inc|IMRN - Company Aggregate Debts|Debt to Book Capitalization Ratio Immuron Limited|IMRN - Company Long-Term Loans and Borrowings|Company Short-Term Debt Immuron|Quick Liquidity immuron.com.au
- net income and valuation multiples indicators:
IMRN - Company Profit|Future Profit Immuron Limited|IMRN - Company Value to Net Income|Future Price to Earnings Immuron Inc|IMRN - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Immuron Limited|IMRN - Operating income before deduction of amortization|Earnings per share for the last twelve months Immuron|IMRN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth immuron.com.au|IMRN - Expected net earnings per share growth this year|Expected earnings per share growth for next year Immuron Limited
Analysis of all company metrics:IMRN - immuron.com.au
Mass-produced product of Immuron Limited

Investors assess the issuer's financial stability through the lens of actual earnings per share. This indicator aggregates net income over four quarters, dividing it by the total number of shares to identify true profitability. For the biotech firm Immuron Limited (IMRN), which invests in immunologists and vaccines, this metric reflects the efficiency of its capital burn. By analyzing the rolling net income per share trend on GURU.Markets, one can uncover hidden write-offs.

Competing companies

Phathom Pharmaceuticals - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters ternspharma.com TERN|IRWD (ironwoodpharma.com) - Net earnings per share for the last 12 months|CURX: Earnings per share for the last four quarters|EVOK (Evoke Pharma, Inc) - Net earnings per share (EPS TTM)|Entero (ENTO) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months RedHill Biopharma (RDHL)|Net earnings per share for the last 12 months Palisade Bio Inc. PALI|Earnings per share for the last twelve months Jaguar Health JAGX|BIOR - Net earnings per share for the last 12 months|MORF: Net earnings per share for the last 12 months